Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Finlabo SIM Spa
$10.00
Provider: Reuters Investment Profile
$20.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Xarelto, Drug Of Bayer AG's Unit, Bayer HealthCare, Recommended In EU For Stroke Prevention After ACS-DJ


Friday, 22 Mar 2013 08:54am EDT 

Dow Jones reported that Bayer AG said the European Committee for Medicinal Products for Human Use, or CHMP, has recommended Bayer HealthCare's anti-clotting drug Xarelto for approval in the European Union when preventing cardiovascular death or stroke. The CHMP has recommended Xarelto 2.5 mg twice-daily in combination with standard antiplatelet therapy for the prevention of atherothrombotic events, like myocardial infarction, cardiovascular death or stroke, after an Acute Coronary Syndrome in adult patients with elevated cardiac biomarkers. The final decision of the European Commission on the approval is expected in the first half of this year. 

Company Quote

95.41
-2.28 -2.33%
15 Aug 2014